Clinical and Radiological Remission of Osteoarticular and Cutaneous Lesions in SAPHO Patients Treated With Secukinumab: A Case Series
Bibliographic record
Abstract
SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome is a rare chronic inflammatory disease involving bone, joints, and skin1. No consensus has been reached on the treatment of SAPHO syndrome and the current options may lead to variable outcomes2. Secukinumab, an antiinterleukin (IL)-17A monoclonal antibody, is a promising novel biologic approved for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis (AS)3. Only a few cases on the use of secukinumab in SAPHO syndrome were reported and have not yielded a unified conclusion4. To further clarify the efficacy of secukinumab in SAPHO syndrome, we report here a case series of 4 patients from our single-center dynamic cohort of SAPHO syndrome (a permanently open cohort continuously accumulating patients)5. All 4 patients were treated with 24-week secukinumab (150 mg subcutaneous once weekly for 4 wks and every 4 wks thereafter), without concomitant nonsteroidal antiinflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), or other biologics. Their clinical conditions, skin lesions, and the whole-body magnetic resonance imaging (MRI) before and after treatment were prospectively collected and evaluated as the preliminary result of a clinical trial, which prematurely ceased due to the outbreak of the coronavirus disease 2019 (COVID-19; caused by SARS-CoV-2). The original clinical trial was registered in the Chinese Clinical Trial Register (ChiCTR1900028064; Supplementary Data 1, available with the online version of this article). …
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.002 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".